# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Lake Street analyst Ben Klieve maintains Evogene (NASDAQ:EVGN) with a Buy and lowers the price target from $5 to $3.5.